Figure 2
Phenotypic analysis of FoxP3+ Treg levels in 5 patients after ASCT compared with those in healthy controls and conventionally treated SLE patients. (A) CD25 and FoxP3 expression on CD4+ T cells at indicated times after ASCT in 5 patients and 1 control. (B) Median FoxP3 expression levels in CD4+ T cells (as determined by flow cytometry in panel A) in 5 patients versus 14 healthy controls, 10 conventionally treated patients with active SLE (SLEDAI ≥ 6), and 14 conventionally treated with inactive SLE (SLEDAI < 6). Group comparisons were performed using the Mann-Whitney U test. (C) FoxP3+ CD4+ Tregs (median absolute counts, as determined by flow cytometry in panel A) in 5 patients versus 14 normal controls. A Mann-Whitney U test was used for group comparison.

Phenotypic analysis of FoxP3+ Treg levels in 5 patients after ASCT compared with those in healthy controls and conventionally treated SLE patients. (A) CD25 and FoxP3 expression on CD4+ T cells at indicated times after ASCT in 5 patients and 1 control. (B) Median FoxP3 expression levels in CD4+ T cells (as determined by flow cytometry in panel A) in 5 patients versus 14 healthy controls, 10 conventionally treated patients with active SLE (SLEDAI ≥ 6), and 14 conventionally treated with inactive SLE (SLEDAI < 6). Group comparisons were performed using the Mann-Whitney U test. (C) FoxP3+ CD4+ Tregs (median absolute counts, as determined by flow cytometry in panel A) in 5 patients versus 14 normal controls. A Mann-Whitney U test was used for group comparison.

Close Modal

or Create an Account

Close Modal
Close Modal